(Q38065082)

English

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer

scientific article published on 05 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Katsuhiko Shimizu

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Takuro Yukawa

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Yuji Hirami

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Riki Okita

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Shinsuke Saisho

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Ai Maeda

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Koichiro Yasuda

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Masao Nakata

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

5 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Targeted oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

237-242

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

https://scigraph.springernature.com/pub.10.1007/s11523-012-0241-x

0 references

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Biological diversity in metastatic neoplasms: origins and implications.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0241-X

21 January 2018

Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23212424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule

1 reference

https://pubmed.ncbi.nlm.nih.gov/23212424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-012-0241-X

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38065082&oldid=1738976818"